- Home
- SWIM vs VALN Comparison
SWIM vs VALN Comparison
Compare SWIM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWIM | VALN |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.8M | 855.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SWIM | VALN |
|---|---|---|
| Price | $6.82 | $10.30 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.75 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 790.6K | 19.5K |
| Earning Date | 03-03-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $533,235,000.00 | $211,089,992.00 |
| Revenue This Year | $8.96 | $3.64 |
| Revenue Next Year | $5.07 | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.12 | ★ 13.48 |
| 52 Week Low | $4.56 | $4.56 |
| 52 Week High | $8.46 | $12.25 |
Technical Indicators
Market Signals| Indicator | SWIM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 54.28 |
| Support Level | $6.30 | $9.62 |
| Resistance Level | $6.87 | $10.32 |
| Average True Range (ATR) | 0.27 | 0.30 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 86.42 | 62.50 |
Price Performance
Historical ComparisonAbout SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.